Beaten-up biotech has some work to do to restore investor confidence. Here's how Gilead Sciences, Valeant Pharmaceuticals, and the entire industry can get back on track in 2017.

Beaten-up biotech has some work to do to restore investor confidence. Here's how Gilead Sciences, Valeant Pharmaceuticals, and the entire industry can get back on track in 2017.

Beaten-up biotech has some work to do to restore investor confidence. Here's how Gilead Sciences, Valeant Pharmaceuticals, and the entire industry can get back on track in 2017. &nbsp;

Healthcare: Top Biotech Resolutions for 2017

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Share Healthcare: Top Biotech Resolutions for 2017

Sign up to save your podcasts

Healthcare: Top Biotech Resolutions for 2017

Healthcare: Top Biotech Resolutions for 2017

More shows like Industry Focus

Motley Fool Hidden Gems Investing

Motley Fool Answers

Rule Breaker Investing

MarketFoolery